1. The future for testing human blood samples lies in automated, rapid test systems called "analyzers." Abbott has their Architect system and Bayer has their Centaur system. Other diagnostic testing companies have other versions. Any mass screening test must be incorporated into an automated system or it will never be successful.
2. The first milestone for the Abbott deal is Abbott's notification to Biocurex of Abbott's successful completion of its feasibility review. Since Abbott licensed the RECAF technology to implement blood tests into Abbott's Architect analyzer system, this first milestone is obviously based on a feasibility review for whether or not that is possible.
3. Everything is meaningless right now except for Abbott announcing that the RECAF technology can and will be incorporated into their Architect analyzer system. When that happens, BioCurex should have sufficient funds to get off the pink sheets, and Wall Street will begin to take notice of the little company called BioCurex.
4. There is no need for BioCurex to go to the unnecessary expense for further independent studies which say that the RECAF serum technology has some specific sensitivity. The only thing that counts right now is what Abbott says about the RECAF technology that they licensed. Abbott is going to either say that it is feasible for the RECAF serum technology to be incorporated into their Architect system or it isn't. If Abbott says "yes" the stock price will fly.
5. It has been almost a year since the Abbott deal was announced. If things were not going well the license would have likely already been returned. Dr. Moro is giving positive hints. Abbott's notification to BioCurex of Abbott's successful completion of its feasibility review requires a milestone payment to BioCurex. Not all of us agree on the amount of money that will be paid with the successful completion of that Milestone, but could be in the millions. Once Abbott makes that announcement and payment, progress should be rapid. Preparations for any necessary clinical trials will likely already have been made. Unlike drug trials, clinical trials of a non-invasive blood test can be done relatively quickly. Those trials and FDA approval could come within a year. A FDA priority review is also possible (since this is a highly sensitive early screening cancer detection test) and that could shorten the time.
6. Also, the time required for FDA approval is somewhat a moot point because Abbott will pay annual minimum royalties to BioCurex commencing with the year ending December 31, 2007 and continuing each subsequent calendar year. That will be a revenue stream for BioCurex. One of the most important Wall Street evaluation factors for a biotech is when will the biotech start making money. Dr. Moro was very smart to have royalty income begin by a certain date that is relatively near. There is no reason to be discouraged with this investment at this particular time. I realize that it is not easy, but be patient. kag
News 
Market Data 
Discover 
